Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Blume-Jensen Peter sold 1,780 Acrivon Therapeutics, Inc. shares (Form 4)
Traded Nov 17, 2026 · Filed Nov 19, 2026
On Nov 17, 2026, Blume-Jensen Peter (Director, President and CEO) sold 1,780 Acrivon Therapeutics, Inc. shares at US$1.45 for US$2,581, leaving 385,355 shares. Filed Nov 19, 2026 (Form 4).
- Sold
- 1,780 shares
- Price
- US$1.45
- Value
- US$2,581
- Holding after
- 385,355 shares (held indirectly)
- Trading plan
- No
- Role
- Director, President and CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Common Stock | Sale | 1,276 | US$1.45 | 2,228,776 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 504 | US$1.45 | 385,355 | Indirect |
Source
Download original · View original at SEC
Related
- Acrivon Therapeutics, Inc.
- Blume-Jensen Peter
- Acrivon Therapeutics, Inc. shareholders
- Form 4 · Blume-Jensen Peter · Aug 27, 2026
- Form 4 · Blume-Jensen Peter · May 20, 2026
- Form 4 · Blume-Jensen Peter · May 18, 2026
- Form 4 · Devroe Eric · Nov 19, 2026
- Form 4 · Peterson Katharine · Nov 19, 2026
- Form 4 · Miller Mary · Nov 19, 2026
- Form 4 · Gamelin Erick · Nov 19, 2026
- Form 4 · Miller Mary · Oct 26, 2026